文献速递关节外科

金黄色葡萄球菌生物膜中耐受性小菌落变体在耐药性出现前形成

Tolerant Small-colony Variants Form Prior to Resistance Within a Staphylococcus aureus Biofilm Based on Antibiotic Selective Pressure.
PubMed 文献 · Clin Orthop Relat Res · 2021-01-01

该体外研究利用多孔膜植入物模型观察金黄色葡萄球菌生物膜在利福平或万古霉素选择压力下的存活与耐药演变。结果显示,初始细菌通过耐受性在生物膜内存活,小菌落变体在穿透性抗生素暴露24小时内从耐受菌群中涌现;利福平联合万古霉素可大幅减少万古霉素耐受菌。

要点

  • 生物膜内金黄色葡萄球菌在利福平选择压力下先以耐受性存活,耐药性随后出现。
  • 万古霉素渗透生物膜差,细菌主要依靠耐受性存活,耐药性贡献有限。
  • 小菌落变体在穿透性抗生素暴露24小时内从耐受菌群中快速涌现。

核心结论

  • 耐受性解释了依赖抗生素清除残留微观生物膜的手术或非手术方式可能随时间失败。
  • 基于生物膜渗透性的耐药性差异出现,可能解释渗透性差的抑制性抗生素治疗依赖细菌控制而限制耐药出现。
  • 该策略未能解决携带小菌落变体形态持续菌的耐受生态位。

研究设计与样本

  • 采用多孔膜作为体外植入物模型,培养发光金黄色葡萄球菌生物膜并同步追踪微菌落扩展。
  • 比较利福平(可穿透生物膜)与万古霉素(穿透生物膜差)对耐受向耐药发展的影响。
  • 膜解离后进行活力计数以区分耐受、耐药和持续菌,并用扫描电镜确认生物膜定量和小菌落形态。

主要发现

  • 抗生素初治金黄色葡萄球菌在利福平选择压力下,生物膜内活菌1.0×10^8 CFU中7.5×10^6 CFU归因于耐药出现,9.3×10^7 CFU归因于耐受发展。
  • 既往暴露于利福平且存在耐药时,耐受介导的存活被消除,生物膜内活菌9.5×10^9 CFU接近利福平耐药菌1.1×10^10 CFU。
  • 万古霉素初治(1.6×10^10 CFU)与万古霉素耐药(1.0×10^10 CFU)菌的生物膜内活菌均不能由耐药出现解释,提示耐受。
  • 利福平加入万古霉素使万古霉素耐受菌从1.5×10^10 CFU降至3.3×10^7 CFU,减少近500倍。
  • 小菌落变体在穿透性抗生素给药后24小时内从耐受菌群中涌现,扫描电镜可见小菌落变体形态且缺乏生物膜相关微结构。

临床怎么用

  • 应认识到生物膜介导的抗生素耐受是假体周围关节感染治疗失败的 neglected 特征。
  • 对渗透性差的抗生素如万古霉素,需注意其可能仅控制细菌而限制耐药出现,但不能清除耐受生态位。
  • 联合使用穿透性抗生素(如利福平)可大幅减少耐受菌,但需关注小菌落变体在耐受菌群中的快速涌现。

局限性

  • 研究为体外多孔膜模型,不能完全模拟体内假体周围关节感染环境。
  • 因起始细菌接种量导致实验变异性,采用相对变化比较,绝对值可能不具统计可比性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The treatment of periprosthetic joint infection (PJI) is focused on the surgical or chemical removal of biofilm. Antibiotics in isolation are typically ineffective against PJI. Bacteria survive after antibiotic administration because of antibiotic tolerance, resistance, and persistence that arise in the resident bacteria of a biofilm. Small-colony variants are typically slow-growing bacterial subpopulations that arise after antibiotic exposure and are associated with persistent and chronic infections such as PJI. The role of biofilm-mediated antibiotic tolerance in the emergence of antibiotic resistance remains poorly defined experimentally. QUESTIONS/PURPOSES: We asked: (1) Does prior antibiotic exposure affect how Staphylococcus aureus survives within a developing biofilm when exposed to an antibiotic that penetrates biofilm, like rifampicin? (2) Does exposure to an antibiotic with poor biofilm penetration, such as vancomycin, affect how S. aureus survives within a developing biofilm? (3) Do small-colony variants emerge from antibiotic-tolerant or -resistant bacteria in a S. aureus biofilm? METHODS: We used a porous membrane as an in vitro implant model to grow luminescent S. aureus biofilms and simultaneously track microcolony expansion. We evaluated the impact of tolerance on the development of resistance by comparing rifampicin (an antibiotic that penetrates S. aureus biofilm) with vancomycin (an antibiotic that penetrates biofilm poorly). We performed viability counting after membrane dissociation to discriminate among tolerant, resistant, and persistent bacteria. Biofilm quantification and small-colony morphologies were confirmed using scanning electron microscopy. Because of experimental variability induced by the starting bacterial inoculum, relative changes were compared since absolute values may not have been statistically comparable. RESULTS: Antibiotic-naïve S. aureus placed under the selective pressure of rifampicin initially survived within an emerging biofilm by using tolerance given that biofilm resident cell viability revealed 1.0 x 108 CFU, of which 7.5 x 106 CFU were attributed to the emergence of resistance and 9.3 x 107 CFU of which were attributed to the development of tolerance. Previous exposure of S. aureus to rifampicin obviated tolerance-mediate survival when rifampicin resistance was present, since the number of viable biofilm resident cells (9.5 x 109 CFU) nearly equaled the number of rifampicin-resistant bacteria (1.1 x 1010 CFU). Bacteria exposed to an antibiotic with poor biofilm penetration, like vancomycin, survive within an emerging biofilm by using tolerance as well because the biofilm resident cell viability for vancomycin-naïve (1.6 x 1010 CFU) and vancomycin-resistant (1.0 x 1010 CFU) S. aureus could not be accounted for by emergence of resistance. Adding rifampicin to vancomycin resulted in a nearly 500-fold reduction in vancomycin-tolerant bacteria from 1.5 x 1010 CFU to 3.3 x 107 CFU. Small-colony variant S. aureus emerged within the tolerant bacterial population within 24 hours of biofilm-penetrating antibiotic administration. Scanning electron microscopy before membrane dissociation confirmed the presence of small, uniform cells with biofilm-related microstructures when unexposed to rifampicin as well as large, misshapen, lysed cells with a small-colony variant morphology [29, 41, 42, 63] and a lack of biofilm-related microstructures when exposed to rifampicin. This visually confirmed the rapid emergence of small-colony variants within the sessile niche of a developing biofilm when exposed to an antibiotic that exerted selective pressure. CONCLUSION: Tolerance explains why surgical and nonsurgical modalities that rely on antibiotics to "treat" residual microscopic biofilm may fail over time. The differential emergence of resistance based on biofilm penetration may explain why some suppressive antibiotic therapies that do not penetrate biofilm well may rely on bacterial control while limiting the emergence of resistance. However, this strategy fails to address the tolerant bacterial niche that harbors persistent bacteria with a small-colony variant morphology. CLINICAL RELEVANCE: Our work establishes biofilm-mediated antibiotic tolerance as a neglected feature of bacterial communities that prevents the effective treatment of PJI.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Manasherob R, Mooney JA, Lowenberg DW, et al. Tolerant Small-colony Variants Form Prior to Resistance Within a Staphylococcus aureus Biofilm Based on Antibiotic Selective Pressure. Clin Orthop Relat Res. 2021. PMID: 33835090. doi:10.1097/CORR.0000000000001740

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。